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Abstract.  Recent studies have indicated that en- 
dothelial cell function includes elaboration of growth 
factors and regulation of coagulation.  In this paper we 
demonstrate that activated coagulation Factor X  (Fac- 
tor Xa), a product of the coagulation mechanism gen- 
erated before thrombin,  induces enhanced release of 
endothelial cell mitogens,  linking these two functions. 
Mitogenic activity generated by cultured bovine aortic 
endothelial cells in response to Factor Xa included 
platelet-derived growth-factor-like molecules based on 
a  radioreceptor assay.  Effective induction of mitogens 
by Factor Xa required the integrity of the enzyme's ac- 
tive center and the presence of the ¥-carboxyglutamic 
acid-containing  domain of the molecule.  Factor Xa- 
induced release of mitogens from endothelium oc- 
curred in serum-free medium and was not altered by 
hirudin or antibody to Factor V, indicating that it was 
a direct effect of Factor Xa and was not mediated by 
thrombin.  Elaboration of mitogenic activity required 
only brief contact between Factor Xa and endothelium, 
and occurred in a time-dependent manner.  Generation 
of enhanced mitogenic activity in response to Factor 
Xa was unaffected by the presence of actinomycin D 
and was not associated with increased hybridization of 
RNA from treated cells to a v-sis probe. Release of 
mitogenic activity was dependent on the dose of Fac- 
tor Xa, being half-maximal at 0.5 nM and reaching a 
maximum by 5 nM.  Radioligand binding  studies 
demonstrated a class of endothelial cell sites half- 
maximally occupied at a Factor Xa concentration of 
0.8 riM.  The close correspondence between the 
parameters of Factor Xa-induced mitogen release and 
Factor Xa binding suggests these sites may be related. 
When Factor X  was activated on the endothelial cell 
surface by Factors IXa and VKI, the Factor Xa formed 
resulted in the induction of enhanced release of mito- 
genic activity. These data suggest a mechanism by 
which the coagulation system can locally regulate en- 
dothelial cell function and vessel wall biology before 
thrombin-induced release of growth factors from 
platelets. 
T 
I~ADITroNALLY, the  response  to  vascular  injury  is 
considered to begin after the endothelium has been 
denuded. Exposure of subendotheliurn  to hemostatic 
components would then lead to platelet deposition, which is 
often assumed to result in fibrin  deposition (34).  Further- 
more, contact of cells in subendothelial  layers of the vessel 
wall  with  growth  factors  would  initiate  smooth  muscle 
proliferation  (1, 5, 20, 30, 31, 39, 48, 62). However, as the 
cells forming the luminal vascular surface,  endothelial  cells 
are  strategically  located  to  function  in  the  regulation  of 
coagulation and modulation of mitogenic signals transmitted 
to the vessel wall. Although endothelial  cell retraction  and 
denudation may play a role in the genesis of vascular lesions 
(18, 19), changes in the vessel wail leading to atherosclerotic 
plaque formation  may occur under a morphologically intact 
endothelium.  Studies  of  small  vessel  wall  injuries  have 
shown that  endothelium covers the denuded areas rapidly, 
perhaps  maintaining  continuity  of  the  monolayer  after 
moderate cell loss (56, 64, 65). These observations suggest 
an alternative view of vessel wall injury in which endothelial 
cell function and dysfunction are central  in the pathogenesis 
of lesion formation. 
Recent studies have indicated that endothelial cell function 
includes  elaboration  of growth  factors  and  regulation  of 
coagulation  (11, 14-16, 21, 27, 43, 51, 60, 61, 73, 80, 83). En- 
dothelial  cells have been shown to produce growth factors, 
including  platelet-derived  growth factor (PDGF)'-Iike pro- 
tein,  raising the possibility that mitogens of endothelial  ori- 
gin could result in proliferation  of vascular smooth muscle 
and  fibroblasts  (14-16, 21,  27,  80,  83).  Induction  of en- 
dothelial cell dysfunction by endotoxin or phorbol esters en- 
hances release of growth factor activity (21). Endothelium 
has also been shown to participate  in both anticoagulant  and 
procoagulant reactions through the presence of specific bind- 
ing sites that modulate coagulant activity on the cell surface 
(51, 61). Although  anticoagulant  mechanisms predominate 
on quiescent endothelial  cells, induction of endothelial  dys- 
function by perturbants can shift this balance toward promo- 
tion of localized clot formation (3, 11, 43). Thus, endothelial 
1. Abbreviations used in thispaper: Factors IXa and Xa, the activated forms 
of Factors  IX  and  X;  Gla-domainless Factor X,  Factor X  modified by 
cleavage of the y-carboxyglutamic acid-containing domain; PDGF, plate- 
let-derived  growth  factor;  PDGFc,  platelet-derived  growth  factor-like 
molecules. 
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tion and growth factor release. 
A  link between atherogenesis and coagulation has long 
been suspected from clinicopathological studies. Accumula- 
tion of fibrin in atherosclerotic lesions is well known (4, 54, 
68-70, 84), and a recent study indicates that an increased ra- 
tio of fibrin II to fibrinogen correlates with more advanced 
lesions (4). Furthermore, thrombin, the final coagulation en- 
zyme in the pathway leading to fibrin formation (13), has 
been shown to induce release of  PDGF-Iike growth factor ac- 
tivity from endothelial cells (32).  Thrombin, however, also 
activates platelets (76), causing release of their intracellular 
stores of  PDGF (82). These findings prompted us to consider 
the hypothesis that products of the activated coagulation sys- 
tem, before the formation of thrombin, could induce local- 
ized perturbation of the endothelium resulting in enhanced 
generation of growth factor activity. If this were true, then 
perturbed endothelium could play a central role in the trans- 
mission of mitogenic signals reaching subendothelial layers 
of the vessel wall even before fibrin deposition occurs. In ad- 
dition,  since the coagulation mechanism is sensitive to a 
wide range of stimuli and is in constant contact with en- 
dothelium,  activated clotting enzymes are  well  suited to 
modulate endothelial cell function. 
These considerations have led us to study products of the 
activated coagulation system that influence the production of 
growth factors by endothelial cells. The results indicate that 
cultured bovine aortic endothelial cells exposed to the acti- 
vated form of coagulation Factor X (Factor Xa) elaborate en- 
hanced amounts of PDGF-like activity. Enhanced release of 
PDGF-like activity occurred in response to relatively low 
concentrations  of  Factor  Xa  (half-maximal  response  at 
0.5 nM) and after only brief exposure of the cells to the clot- 
ting enzyme, suggesting that this coagulation factor-endo- 
thelial  cell  interaction  might  occur  under  physiological 
conditions. Furthermore, activation of Factor X on the endo- 
thelial cell surface resulted in release of PDGF-like activity 
linking cell surface coagulant events and generation of mito- 
gens. These data suggest a mechanism by which vessel wall 
biology and endothelial cell function can be locally regulated 
by the coagulation system before thrombin-induced release 
of PDGF from platelets. 
Materials and Methods 
Cell Culture 
Primary cultures of bovine aortic endothelial cells were isolated by previ- 
ously described methods (28) and grown in 10% bovine adult serum. Serum 
was heat-inactivated for 30 min at 560C. Endothelial cells were subcultured 
in Waymouth's  Medium (Gibco, Grand Island, NY) supplemented with so- 
dium bicarbonate, nonessential amino acids, sodium pyruvate, and 10% se- 
rum as described by Schwartz (63). Endothelium was passaged in 75-era  2 
flasks (Coming Glass Works, Coming Science Products, Coming, NY) 
with 0.05 % trypsin at a split ratio of 1:3 and used for experiments from pas- 
sages 5-15. Three separate cell isolates gave comparable results. Swiss 313 
cells were routinely subcultured every 3-4 d in Dulbeeeo's modified Eagle's 
media containing 10% bovine serum (15). Human dermal fibroblasts were 
derived from explants and maintained in Waymouth's medium containing 
10% bovine whole blood serum. 
Endothelial cells derived from human umbilical cord veins were pre- 
pared according to the method of Jaffe et al. (33). Human endothelial cell 
cultures contained no monocyte/macrophage-contaminating  cells, as judged 
by morphologic criteria and by cytofluorometry using OKM2, a monoclonal 
antibody reactive with most human monocytes/maerophages (8). 
Preparation of  Conditioned Medium and Assays 
Confluent cultures of endothelial cells in 35-mm Petri dishes (Falc~an Lab- 
ware, Oxnard, CA) were washed once with phosphate-buffered  saline (PBS) 
(pH 7.4) (Gibco) and then placed in fresh serum-free Waymouth's medium 
containing 0.1% bovine serum albumin (BSA; RIA grade; Sigma Chemical 
Co., St. Louis, MO), 1.8 mM CaCI2, and 25 mM Hepes (pH 7.4).  Coagu- 
lation factors were added to dishes for the indicated times. Conditioned 
medium was centrifuged (4,000 g) for 10 min to remove debris and stored 
at 4°C before assay (within 5 d). Rndioreceptor and mitogenic assays were 
carried out as described below using purified human PDGF  (55)  as  a 
standard. 
A radioreceptor assay measuring competition between PDGF-like mole- 
cules (PDGFc) in endothelial cell superuatants and t25I-PDGF for binding 
to PDGF receptors was carded out as described by Bowen-Pope and Ross 
(7). Subconfluent human diploid fibroblasts were used 2-10 d after plating 
(1.5  ×  104 cells/cm  2)  in 2.1-cm  2 wells (Costar,  Data Packaging Corp., 
Cambridge, MA) containing 1 mi of medium with 1% plasma-derived se- 
rum (79). The cells were cooled to 4°C on an ice tray and washed with 0.5 
ml ice-cold binding medium (Ham's F-12 medium without bicarbonate con- 
taining 25 mM Hepes buffer [pH 7.2] and BSA [2 mg/ml]). The medium 
was replaced with an aliquot of the endothelial cell-conditioned medium 
plus binding medium in a total volume of 1.0 ml. The cultures were in- 
cubated at 4°C with rapid mixing for 4 h. After aspiration of the test sub- 
stance and rinsing with binding medium, 0.5 ng t25I-PDGF [rndioiodina- 
tion of PDGF was carded out as described [7]) was added in 0.5 ml binding 
medium, and the incubation was continued at 40C for an additional hour. 
The medium was then aspirated and the cells washed three times with 1 rnl 
of PBS (4°C) containing 1 mg/ml BSA. Bound radioactivity was determined 
by solubilizing the cells with 1% Triton X-100 containing BSA (1 mg/ml). 
Nonspecific binding, measured in the presence of at least a 100-fold excess 
of  unlabeled PDGE was <12 % of specific binding. Standard curves, derived 
from wells containing purified unlabeled PDGF, were used for qnantitation 
of PDGF-like protein. Standard deviations were generally <15 %. 
The mitogenic activity of endothelial cell-conditioned medium was de- 
termined by the incorporation of [3H]thymidine into TCA-precipitable ma- 
terial by confluent cultures of 3T3 cells (15). All samples were tested at 
several dilutions in triplicate; standard deviations were <10% within an as- 
say. The results of different assays carded out on different endothelial cell 
lines at different passages varied from 10-30%. Units of activity were deter- 
mined for each assay from a standard curve using purified PDGE One unit 
of mitogenic activity was defined as the [3H]thymidine incorporation stim- 
dated by 0.2 ng of PDGF compared with a control consisting of medium 
containing 1% plasma-derived serum (26).  Stimulation of [3H]thymidine 
incorporation (27) under these conditions directly correlates with cellular 
proliferation. Where indicated, the IgG fraction of goat monospecific anti- 
body to human PDGF (6) was included in assay mixtures at a concentration 
sufficient to inhibit  10 ng/ml PDGE  This antibody has been previously 
shown to neutralize the mitogenic effect of human PDGF (6). 
Endothelial cell RNA synthesis was determined by the incorporation of 
[3H]uridine  into TCA-precipitable material by endothelial cell monolayers. 
Monolayers in 35-mm dishes were incubated with 1.0 ml of [3H]uridine 
(3.5 IxCi; 25 Ci/mmol) in serum-free medium for 1 h at 37°C. After remov- 
ing the medium, cultures were rinsed four times with 2 ml of  cold 10 % TCA. 
The precipitated material was solubilized using 0.5 M sodium hydroxide and 
radioactivity determined in a liquid scintillation counter. Standard devia- 
tions in triplicate determinations were <10%. 
Hybridization of endothelial cell RNA with the v-sis eDNA probe was 
carded out by a modification of the method of Chirgwin et al. (10). In brief, 
endothelial cell RNA was extracted from a pellet of 5  x  106 cells using 
5 M guanidinium isothiocyanate. RNA was sequentially precipitated in 4 M 
lithium chloride/10 mM Tris (pH 7.6) at 4°C (9), dissolved in 0.1% SDS/10 
mM Tris (pH 7.6)/1 mM EDTA, phenol/chloroform extracted and precipi- 
tated in 100 mM NaCl/ethanol (1:2, vol/vol) at -70°C (45). RNA was then 
heated for 15 min at 600C  in 3.0 M NaCI/0.3 M sodium citrate/formalde- 
hyde, and spotted onto nitrocellulose paper previously equilibrated with the 
same buffer.  Hybridization was carded out for 18 h to a 32p-labeled nick- 
translated v-sis eDNA probe (57) as described (17), washed, and exposed 
to film. The v-sis probe was generously provided by Dr. R. Gallo (National 
Institutes of Health, Bethesda, MD) and rat skin fibroblasts, which do not 
express v-sis hybridizable RNA, by Dr. R. Meek (University of Washing- 
ton, Seattle, WA). 
Preparation of Coagulation Factors 
Bovine coagulation proteins were used throughout. Factor Xa, purified to 
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tion with the Factor X activator from Russell's viper venom (35) coupled 
to CNBr-Sepharose (Pharmacia Fine Chemicals, Piscataway,  NJ) as de- 
scribed previously (70). Activation  was complete by 10 min as judged by 
coagulant assay (100 U/mg) performed by the method of Bajaj and Mann 
(2) and by SDS PAGE, which showed complete cleavage of the zymogen 
(24).  Factor  Xa  was  inactivated  by  either  antithrombin III  (37),  di- 
isopropylfluorophosphate,  or (p-amidinophenyl) methanesuifonyl fluoride 
(38), as follows.  Incubation of Factor Xa (50 riM) with antithrombin III 
(1 gM) for 1 h at 37°C resulted in complete loss of Factor Xa coagulant ac- 
tivity.  Antithrombin III  was  purified  to  homogeneity according to  the 
method of Mahoney et al. (44), and the final product exhibited an inhibitory 
activity of 1.0 U thrombin/mg. A 10-fold molar excess of (p-amidinophe- 
nyl)-methanesulfonyl  fluoride  (Calbiochem-Behring Corp., La Jolla, CA) 
inactivated  Factor Xa after 60 min at 37°C as described (38).  Diisopro- 
pylfluorophosphate  (2 mM) blocked Factor Xa (1 IxM)  coagulant activity af- 
ter 5 min at 37°C. Unreacted (p-amidinophenyl) methanesulfonyl  fluoride 
and diisopropylfluorophosphate  were  removed  by dialysis.  Factor X was 
radioiodinated by the solid-state lactoperoxidase  method (12) using the En- 
zymobead Reagent (Bio-Rad  Laboratories, Richmond, CA),  as described 
previously (72).  t25I-Factor X was then activated  as described previously 
for unlabeled Factor X. The iodination procedure did not affect Factor Xa 
coagulant activity and the final product had a specific radioactivity of  0.8-1.6 
x  104 cpm/ng. Preparations of 125I-Factor Xa were used immediately  for 
binding studies. 
Factor X modified by cleavage of the ~,-carboxyglutamic acid-containing 
domain (the amino-terminal ll-44] peptide from the light chain) (Gla- 
domainless Factor X) was prepared by reacting Factor X with ~x~chymotryp- 
sin (400:1, wt/wt) until <0.1% of the original coagulant activity remained 
as described (49, 65). Gla-domainless Factor X was then purified on QAE- 
Sephadex (Pharmacia Fine Chemicals) (47, 65) and activated as described 
for Factor X except that activation was carried out in the presence of 10 mM 
CaCI2 and for 18 h. Gla-domainless Factor Xa and native Factor Xa were 
equally effective on a molar basis in the hydrolysis of Bz-Ile-Glu-Gly-Arg-p- 
nitroanilide (67) (see below),  though Gla-domainless Factor Xa had con- 
siderably reduced coagulant activity as reported previously  (67). 
Factor IX was purified  to homogeneity (250 U/mg) by the method of 
Fujikawa et al. (23), and was activated during incubation with Factor XIa 
bound to CNBr-Sepharose as described previously  (72). Factor IXa (22.2 
gM) was inactivated by incubation with dansyl-glu-gly-arg-chloromethylke- 
tone (600 gM) (Calbiochem-Behring Corp.) for 3 h as described by Lollar 
and Fass (40). Factor VIII, prepared by the method of Vehar and Davie (7g), 
was 28-fold activatable by thrombin and had a specific coagulant activity 
of 4,500 U/mg.  Prothrombin (13 U/mg) and ~t-thrombin (2.5 NIH U/gg) 
were  prepared  as  described previously  (42,  46).  To  remove  any trace 
amounts of Factor Xa from the thrombin, thrombin preparations were chro- 
matographed over an afligel 10 column with immobilized rabbit antibovine 
Factor X/Xa IgG. The pass-through fractions had thrombin concentrations 
of ,'~2 mg/ml and <5 ng/ml of Factor Xa (the limit of detection in a Factor 
X/Xa radioimmunoassay).  These preparations were diluted appropriately 
and used in endothelial cell experiments.  Thrombin (2.5 NIH U) was inacti- 
vated, as judged by coagulant assay, after a 1-h incubation with hirudin (6.0 
U; Sigma Chemical Co.) (47). 
Factor X Activation on, and Factor Xa Binding to, 
Endothelial Cells 
Factor X activation over endothelial cell monolayers was studied by incubat- 
ing  confluent endothelial cells  in 0.79-cm  2 well  with  Factors  IXa  (0.2 
pmol/ml), VIII (1.5 U/ml), and X (300 pmol/ml) in incubation buffer (10 
mM Hepes |pH 7.45] containing 137 mM NaCI, 4 mM KCI, U mM glucose, 
2.5  mM CaCI2, and 5  mg/ml BSA)  (74).  Where indicated,  active  site- 
blocked Factor IXa replaced  native Factor IXa. At timed intervals, one ali- 
quot (0.1 ml) was removed and added to 0.4 ml of 50 mM Tris (pH 7.9), 
175 mM NaCI,  5 mM EDTA, and 0.5 mg/ml ovalbumin.  Factor Xa forma- 
tion was assessed  using the chromogenic substrate Bz-lle-Glu-Gly-Arg-p- 
nitroanilide (77) by adding the entire 0.5-ml sample along with 0.1 ml of 
substrate and measuring the change in absorbance at 405 nm. This assay 
was sensitive to 0.4-0.5 nM Factor Xa and the amount of Factor Xa formed 
was determined by comparison with a  standard  curve made with known 
amounts of Factor Xa. 
Binding studies were carried out after washing confluent endothelial cells 
in 0.32-cm  2 wells  twice  with Hanks balanced salt solution.  Incubation 
buffer was added along with ~25I-Factor  Xa and other coagulation  proteins 
as indicated to achieve a final volume of 0.1 ml. Binding assays were carried 
out for 90 rain at 4°C. This amount of time was sufficient to allow maximal 
binding at the lowest concentrations of Factor Xa employed.  Binding was 
terminated by five rapid washes (0.1 ml/wash) over 5 s with ice-cold incuba- 
tion buffer and cells were solubilized with 0.2 N  NaOH,  1% SDS,  and 
10 mM EDTA. Total binding was measured in wells  incubated with mi_ 
Factor Xa alone. Nonspecific binding was estimated using a 250-fold molar 
excess of unlabeled Factor Xa at each concentration of mI-Factor Xa. Ad- 
ditional amounts of unlabeled Factor Xa did not affect the results.  Non- 
specific binding was essentially linear with respect to radioligand concentra- 
tion. Nonspecific  binding was subtracted from total binding at each point 
in order to determine specific binding. Binding data were fit to the equilib- 
rium binding equation of Klotz  and Hunston (36),  assuming a  one-site 
model. A nonlinear least squares program (SAS Institute,  Cary,  NC) was 
used to obtain the best fit curve, to solve for the number of sites per cell 
and association constant, and to determine the standard error. A plot of 
residuals versus free radioligand  concentration for the binding data shown 
in Fig. 5 indicated no systematic error was involved in fitting binding to the 
one-site model (data not shown). 
Results 
Previous  studies  have  demonstrated  that  endothelial  cells 
have specific binding sites for Factors IX, X, and their acti- 
vated forms in addition to thrombin (41,  51).  This led us to 
examine if incubation of confluent monolayers of bovine aor- 
tic  endothelial  cells  with  these  coagulation  proteins  in 
serum-free medium would result in enhanced elaboration of 
mitogenic activity (Table I). The coagulation factors present 
normally  in  the  plasma,  Factors  IX  and  X,  and  pro- 
thrombin (at their approximate plasma concentrations), did 
not  induce generation  of mitogenic activity by  endothelial 
cells compared with controls.  The activated form of Factor 
IX was  also ineffective.  Factor Xa,  the central coagulation 
enzyme  linking the intrinsic and extrinsic  pathways  of the 
clotting system (13), induced enhanced release of mitogenic 
activity. Factor Xa had no effect on endothelial cell viability 
as  evidenced  by  lack  of  increased  lactate  dehydrogenase 
release  during  exposure  of cells  to  the  enzyme  (data  not 
shown).  Furthermore,  mitogenic  activity  shown  in  the 
figures  was  in all  instances heat  stable,  since treatment of 
samples at 56°C  for 30 min had no effect on the mitogenic 
activity measured.  Because Factor Xa is a product of earlier 
stages of coagulation before thrombin formation occurs,  we 
chose to characterize its effect on endothelial cell growth fac- 
tor release. Thrombin also caused enhanced release of mito- 
.genic activity as  reported previously  (32). 
Table L Effect of Coagulation Factors on Release 
of Growth Factor Activity  from Endothelial Cells 
Coagulation factor  Concentration  Mitogenic activity 
nM  U/ml 
Factor IX  70  0.7 
Factor IXa  40  1.0 
Factor VIII  1 U/ml  0.7 
Factor X  200  0.3 
Factor Xa  4  4.5 
Prothrombin  800  0.4 
Thrombin  50  1.5 
Thrombin  100  2.3 
No addition  -  0.7 
Confluent cultures of endothelial cells were incubated for 3 h at 37°C with the 
indicated coagulation factor and conditioned medium was assayed for mitogen- 
ic activity using 3T3 cells as described  in Materials and Methods. Results 
shown represent the mean of triplicate determinations of units of mitogenic ac- 
tivity per milliliter. Standard deviations were <10%. 
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Forms of  Factor Xa on the Elaboration  of  Mitogenic 
Activity by Endothelial  Cells 
Coagulation factors  added  Mitogenic activity 
U/ml 
Factor Xa  6.75 
Factor Xa-antithrombin III  0.9 
DIP-Factor Xa*  1.5 
pAPMS-Factor Xa  2.0 
Gla-domainless Factor Xa  1.0 
No addition  0.8 
Confluent  cultures of endothelial cells were incubated  for 3 h with native  or 
modified Factor Xa at a final enzyme concentration  of 8 nM.  Conditioned  me- 
dia were assayed for mitogenic activity using 3T3 cells as described in Materi- 
als and Methods.  Results shown represent the mean of triplicate  determinations. 
Standard deviations were <10%.  Modified  forms of Factor Xa were prepared 
as described in Materials and Methods.  Antithrombin  III alone had no inhibito- 
ry effect on the assay. 
* DIP-Factor  Xa,  diisopropylfluorophosphate-treated  Factor Xa;  pAPMS-Fac- 
tor Xa,  (p-amidino-phenyl)-methanesulfonyl-Factor  Xa. 
Figure  1.  Factor  Xa-induced  release  of mitogenic  activity  and 
PDGFc by endothelial cells. Confluent endothelial cell monolayers 
were incubated with serum-free medium in the presence or absence 
of Factor Xa (0.5 nM) for 16 h at 37°C. Serial dilutions of condi- 
tioned medium were then collected and tested in the [3H]thymidine 
incorporation  assay using 3T3 cells and the PDGF radioreceptor 
assay as described in Materials and Methods. Total [3H]thymidine 
incorporation  is shown on the left ordinate  (demarcations on left 
side of axis) and is correlated with comparable units of mitogenic 
activity (demarcations on right side of axis). The concentration of 
PDGFc as determined from the radioreceptor assay is shown on the 
right  ordinate.  The  dilution  of serum-free  medium  from cells 
treated with Factor Xa or controls is shown on the abscissa. Values 
represent the mean of  triplicate determinations. Standard deviations 
in the [3H]thymidine incorporation and radioreceptor  assays were 
<10 and 15%, respectively. Open bars, mitogenic activity; shaded 
bars; PDGFc concentration. 
The mitogenic activity of conditioned medium from Fac- 
tor Xa-treated endothelial cells was detectable up to a  1:50 
dilution in the [3H]thymidine assay using 3T3 cells (Fig.  1). 
Considerably  lower  amounts  of  mitogenic  activity  were 
released by untreated endothelial cells. Although this assay 
was  sensitive for the  detection  of endothelial  cell-derived 
mitogenic activity, to better characterize the molecular mito- 
gen species in  the  conditioned  medium,  the  PDGF-radio- 
receptor assay was carried out (Fig.  1). The results indicate 
that mitogenic activity released by Factor Xa-treated endo- 
thelial cells does contain molecular species that inhibit bind- 
ing of purified t25I-PDGF to its receptor. To further examine 
the contribution of PDGF and PDGF-like molecules to the 
mitogenic activity released by endothelium  in  response to 
Factor Xa,  antiserum to PDGF was used.  Because bovine 
PDGF has not been purified and our antiserum to human 
PDGF (6) does not neutralize bovine PDGF activity, it was 
necessary to use cultured human umbilical vein endothelial 
cells for these studies.  When Factor Xa (0.5  nM)  was in- 
cubated with cultured human endothelium  (passage 2)  for 
14 h in serum-free medium, >90% of the mitogenic activity 
released  could  be  neutralized  by  the  IgG  fraction  of  a 
monospecific goat anti-PDGF antiserum (a quantity of an- 
tiserum  sufficient  to  neutralize  10  ng/ml  of  PDGF  was 
added). These data suggest that the mitogenic species elabo- 
rated by endothelium in response to Factor Xa can be largely 
accounted for by PDGF or immunologically similar mole- 
cule(s). 
To further study the effect of Factor Xa on release of en- 
dothelial cell mitogenic activity, modified forms of Factor Xa 
were studied (Table II). Native Factor Xa induced elabora- 
tion of mitogenic activity, but Factor Xa inactivated by an- 
tithrombin III was no longer effective. Since antithrombin III 
is a relatively large molecule (Mr •58,000)  (44) compared 
with  Factor  Xa  (Mr  40,000)  (24),  the  inhibitor  could  be 
masking multiple sites on the enzyme in addition to the ac- 
tive site. This led us to examine other forms of Factor Xa. 
Factor Xa inactivated at its active site by either diisopropyl- 
fluorophosphate  or  (para-amidinophep.yi) methanesulfonyl 
fluoride was ineffective in causing release of endothelial cell 
mitogenic activity.  Factor Xa can also be modified by re- 
moval of the amino terminal 44 residues from the light chain. 
Table IlL Effect of  Hirudin and Antibody to Factor V 
on Elaboration  of  Mitogenic Activity by Endothelial  Cells 
Protein(s)  added  Mitogenic activity 
U/ml 
Factor Xa  6.3 
Factor Xa +  hirudin  6.3 
Factor Xa +  anti-Factor V  IgG  6.0 
Factor Xa +  nonimmune IgG  5.9 
anti-Factor V  IgG  0.9 
Nonimmune IgG  0.9 
Hirudin  0.8 
No addition  0.8 
Confluent  cultures of endothelial cells were incubated  for 45  min with anti- 
Factor V or nonimmune IgG, and then Factor Xa alone or in the presence  of 
hirudin was added for 3 h at 37°C. Conditioned medium was assayed for mito- 
genic activity using 3T3 cells as described in Materials and Methods.  Results 
shown represent  the mean of triplicates.  Standard deviations were <10%. The 
final concentrations  of reaction mixture components  were: Factor Xa (4.4 riM), 
hirudin (0.5 U/ml),  anti-Factor V lgG (200 gg/ml), and nonimmune  IgG (300 
~g/~). 
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Figure 2. Time course of Factor Xa-induced release of mitogenic 
activity and  PDGFc by endothelial cells.  Confluent endothelial 
cells were incubated in serum-free medium with or without Factor 
Xa (0.5 riM) for the indicated times. Aliquots were withdrawn and 
tested for mitogenic activity in the  [3H]thymidine incorporation 
assay using 3T3 ceils and for PDGFc in the radioreceptor assay, as 
described in Materials and Methods. Units of  mitogenic activity are 
shown on the left ordinate and PDGFc is shown on the right or- 
dinate. Symbols: supernatants from Factor Xa-treated endothelial 
cells assayed in the mitogenic (o) and radioreceptor (o) assays; su- 
pernatants from control endothelial celts assayed in the mitogenic 
(A) and radioreceptor (A) assays. The mean of triplicate determi- 
nations is shown. Standard deviations in the [3H]thymidine and 
radioreceptor assays were <10 and 15 %, respectively. 
This form of Factor Xa, Gla-domainless Factor Xa, does not 
interact effectively with phospholipid membrane surfaces or 
other coagulation factors due to lack of the ),-carboxyglu- 
tamic acid residues, though its intrinsic amidolytic activity 
for small substrates is unaltered (52, 67).  Gla-domainless 
Factor Xa was not effective in the induction of endothelial 
cell mitogen release. Thus, for optimal release of endothelial 
cell mitogenic activity, both the integrity of the active site 
and the presence of the y-carboxyglutamic acid-containing 
domain of the molecule are required. Factor Xa-induced re- 
lease of mitogenic activity was not due to lipopolysaccharide 
in the preparation since addition of antithrombin 11I or treat- 
ment of the enzyme with diisopropylfluorophosphate blocked 
the enzyme's effect. Furthermore, treatment of lipopolysac- 
charide with antithrombin HI or diisopropylfluorophosphate 
under  these  conditions  did  not  affect endotoxin-induced 
mitogen elaboration (data not shown). 
Since Factor Xa can interact with endothelial cell Factor 
V resulting in prothrombin activation (60, 72), it was neces- 
sary to determine if this sequence of events could account for 
Factor Xa-induced mitogen release (Table III). To minimize 
the presence of the substrate, prothrombin, all experiments 
were carried out under serum-free conditions after washing 
monolayers extensively. In previous studies,  we have ob- 
served only low affinity and rapidly reversible binding of 
prothrombin  to  endothelium,  which  could be completely 
eluted under these conditions (Stern, D., and P.  Nawroth, 
unpublished observation). Addition of  the thrombin inhibitor 
hirudin  to  Factor Xa-endothelial cell incubation mixtures 
had no effect on mitogen elaboration. The presence of anti- 
body to bovine Factor V at a concentration that blocks pro- 
thrombin activation on the endothelial cell surface by >90 % 
(72) also had no effect  on mitogen release in response to Fac- 
tor Xa. Taken together, these findings suggest that Factor Xa- 
induced mitogen release is predominately due to a  direct 
effect of  Factor Xa on endothelium. Although the endotlxelial 
cell site mediating this interaction with Factor Xa is unclear, 
Factor V on the cell surface is probably not involved. 
Endothelial cell mitogen elaboration induced by Factor Xa 
was  dependent on the incubation time (Fig.  2).  The time 
course of mitogen release appears to be biphasic with an ini- 
tial period of release that reaches an apparent maximum by 
3 h and a second phase of release evident by 4 h that con- 
tinues to increase steadily. Since activated coagulation fac- 
tors such as Factor Xa are rapidly inhibited under physiologi- 
cal conditions, release of mitogenic activity after incubation 
periods as short as 2 rain was an important observation. 
To investigate whether RNA synthesis was required for in- 
duction of mitogen release, actinomycin D (0.5 gg/ml) was 
added to cultures 3 h before the addition of Factor Xa (Table 
IV). This concentration of actinomycin D blocked total uri- 
dine incorporation by 90 % and did not decrease endothelial 
cell viability until after 24 h of incubation. Total release of 
mitogenic activity after 2.5 and 24 h of exposure to Factor 
Xa was identical in the presence or absence of actinomycin 
D. Consistent with these results, cytoplasmic dot blot hybrid- 
ization experiments (Fig.  3)  showed no  significant differ- 
ences by densitometric scanning  in endothelial celt RNA 
hybridizing with the v-sis probe whether cultures had been 
incubated with Factor Xa (5 nM; 16 h of incubation) or not. 
By  this  time,  considerable  mitogenic  activity  had  been 
released  (Fig.  2).  These  results  suggest  that  Factor  Xa- 
induced release of  mitogenic activity was independent of new 
RNA synthesis and may reflect the presence of a preformed 
intracellular pool of mitogen. In this context, heat-treated ly- 
sates of frozen-thawed control endothelial cells did not con- 
tain  significant mitogenic  activity  as  previously  reported 
(21, 29). Thus, Factor Xa may induce translational or post- 
translational processing of the molecules responsible for en- 
dothelial  cell  mitogenic  activity.  To  distinguish  between 
Table IV. Effect of  Actinomycin D on 
Factor Xa-induced Mitogen Release 
Incubation times 
2.5  h  24 h 
Mitogenic  Mitogenic 
Incubation conditions  activity  PDGFc  activity  PDGFc 
Utmt  ng/ml  Utml  nglrnl 
No addition  -  0.08  0.4  0.20 
Actinomycin D  -  0.13  1.3  0.36 
Factor Xa  2.6  0.36  10.0  2.0 
Factor Xa +  actinomycin D  2.8  0.44  10.5  1.85 
Confluent  endothelial  cell monolayers  were  preincubated  for 3  h  with  ac- 
tinomycin D (0.5 pg/ml). Factor Xa (0.5 nM) was added next (time 0) and con- 
ditioned  media  were collected  at  2.5  and  24  h.  Conditioned  media  were 
dialyzed  (to remove  actinomycin  D) against  1 mM ammonium  bicarbonate, 
lyophilized,  dissolved  in  a  volume  of media  equal  to  the  original  sample 
volume, and assayed for mitogenic activity (using 3T3 cells) and PDGFc. Sam- 
ples were assayed in triplicate. Standard deviations were <10%. The means are 
shown. Under these conditions, controls demonstrated that actinomycin D had 
no direct inhibitory affect on the assay. 
Gajdusek et al.  Endothelial  Cell Mitogens  423 Figure 3. Hybridization of RNA to the v-sis probe from Factor Xa- 
treated  and  control  endothelial  cells.  Confluent  endothelial  cell 
monolayers were incubated with or without Factor Xa, RNA was 
extracted, adsorbed to nitrocellulose paper, and hybridized with a 
32P-nick-translated v-sis  probe  as  described  in  Materials  and 
Methods. A, hybridization to RNA obtained from control rat skin 
fibroblasts. B, RNA from endothelial cells incubated in serum-free 
medium alone.  C and D, from endothelial cells exposed for 16 h 
to Factor Xa, 22.2 and 4.4 riM, respectively. Samples from left to 
right are serial dilutions, containing 6.7, 1.7, and 0.4 Ixg of RNA, 
respectively. 
these possibilities, experiments were carried out using cyclo- 
heximide. When cycloheximide was tested at 1 lag/ml,  total 
protein synthesis was decreased by 80%  and Factor Xa (5 
nM)-induced mitogen release was still unaffected. Attempts 
to more completely block protein synthesis at higher cyclo- 
heximide concentrations were inconclusive due to poor en- 
dothelial cell viability at these levels of inhibitor. Studies at 
the  posttranslational  level using  either  paraformaldehyde- 
(1%),  formaldehyde- (1%),  or  methanol-  (50%)  fixed en- 
dothelial cell monolayers indicated that Factor Xa released 
comparable amounts  of mitogenic activity compared with 
untreated, viable controls (data not shown).  Since the fixed 
cells showed no significant incorporation of radiolabeled uri- 
dine or leucine, Factor Xa-induced mitogen release appears 
to be independent of cellular biosynthetic processes. Factor 
Xa might act by directly cleaving a  mitogen precursor al- 
ready present in the cell or on the cell surface. 
Elaboration of enhanced endothelial cell mitogenic activ- 
ity was dependent on the concentration of Factor Xa added 
in a biphasic manner (Fig. 4). At lower levels of Factor Xa, 
release of mitogen increased  from 0.8  to 2.7  U/ml,  being 
maximal at a Factor Xa concentration of 5 nM (5.4 U/ml). 
Half-maximal release of mitogenic activity occurs at a Factor 
Xa concentration of ~0.5 nM. These levels of Factor Xa may 
be achieved under physiological conditions and are reached 
when Factor Xa is activated on the endothelial cell surface, 
as will be described below. As higher concentrations of Fac- 
tor Xa are added to the endothelial cell (>11 nM),  steadily 
increasing release of mitogenic activity was observed. Simi- 
lar studies carried out with Factor X  (Fig. 4) demonstrated 
that the zymogen was ineffective in the induction of mitogen 
release. 
The release of mitogenic activity in response to Factor Xa 
appeared to saturate in the first phase of the dose-response 
curve (Fig. 4), suggesting that Factor Xa-endothelial cell in- 
teraction might be due to a limited number of binding sites. 
To better characterize the involvement of endothelium in this 
phenomenon, radioligand binding studies were carried out 
(Fig. 5).  The binding of ~25I-Factor Xa to endothelial cells, 
studied at 4°C to prevent endocytosis, was saturable. Semi- 
logarithmic  plots  of  the  binding  data  demonstrate  half- 
maximal binding at a Factor Xa concentration of 0.8  +  0.14 
nM and at saturation of 2.1  +  0.3  x  10  4 molecules bound 
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Figure  4.  Dependence  of re- 
leased  mitogenic  activity  on 
the concentration of Factor Xa 
incubated  with  endothelial 
cells. Confluent  endothelial cell 
cultures  in  serum-free  medi- 
um were  incubated  3 h  with 
increasing  concentrations  of 
Factor  Xa (o)  and  Factor  X 
(X). Conditioned medium was 
assayed for mitogenic activity 
in the [3H]thymidine incorpo- 
ration assay using 3T3 cells as 
described  in  Materials  and 
Methods.  Data shown are the 
means  of triplicate  determi- 
nations.  Standard  deviations 
were <15 %. 
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Figure 5. Binding of ~5I-Factor Xa to cultured bovine aortic endothelial cells. Endothelial cell monolayers were incubated with varying 
concentrations  of t25I-Factor Xa. The protocol is described  in Materials and Methods.  Nonspecific binding was determined  from wells 
incubated with a 250-fold molar excess of unlabeled Factor Xa. Specifically bound t25I-Factor  Xa is plotted vs. the free concentration of 
Factor Xa. The curves indicate the best-fit line as described by nonlinear  least-squares analysis. 
per endothelial cell. These binding parameters are similar to 
the preliminary results reported by Rodgers and Shuman for 
Factor Xa binding to cultured bovine aortic endothelial cells 
(59) and a class of reversible binding sites observed by us on 
bovine aortic segments (72). Results of clearance studies of 
radiolabeled Factor Xa in vivo in the mouse are also consis- 
tent with the presence of endothelial cell binding sites (22). 
Recent  studies  have demonstrated that endothelium  can 
promote the activation of Factor X (74). The subsequent in- 
teraction of the Factor Xa thus formed with the endothelial 
cell could then provide a localized signal causing release of 
mitogens. If this were true, this would suggest the possibility 
of local regulation of mitogen generation due to interaction 
of the coagulation system with the vessel wall. To test this, 
Factor IXa-VM-mediated activation of Factor X was exam- 
ined over endothelial cell monolayers (Fig.  6).  A  low con- 
centration of Factor IXa (0.2 riM) was employed along with 
physiological levels of Factors VM and X. Factor Xa forma- 
tion occurred (Fig 6 A, e) and was accompanied by the re- 
lease ofmitogen from the endothelium (Fig. 6 B, II). Release 
of mitogen required Factor Xa formation, since substitution 
of  active  site-blocked  Factor  IXa  for  native  Factor  IXa 
prevented Factor Xa formation (Fig.  6  A,  o) and mitogen 
release (Fig. 6 B, M). Furthermore, none of the initial reac- 
tion components has the ability to cause enhanced release of 
mitogen from the endothelium (Table I). These results indi- 
cate that after Factor X  activation has occurred on the en- 
dothelial cell surface and the product has been inactivated 
(Factor  Xa  inactivation  would  be  complete  after  several 
minutes in the presence of plasma protease inhibitors), a cir- 
cumscribed  area  on  endothelium  continues  to  elaborate 
mitogenic activity. 
Discussion 
The  results  reported  here  demonstrate  that  cultured  en- 
dothelial cells elaborate increased amounts of mitogenic ac- 
tivity, including  PDGFc,  after incubation  with Factor Xa. 
The induction of endothelial cell mitogens by Factor Xa indi- 
cates a link between activation of the coagulation system and 
the regulatory role of endothelium.  Although quiescent en° 
dothelium does not induce activation of coagulation, pertur- 
bation of endothelial cells by agents such as endotoxin and 
phorbol esters can lead to the induction of tissue factor (3, 
43,  60),  a  cofactor for the  initiation  of coagulation  (53). 
These same agents have also been shown to augment mitogen 
release by endothelium  (21).  Endothelial  cell tissue factor 
promotes Factor VII/VIIa-mediated activation of Factor X 
•  directly and via Factors VM and IX (75). Factor Xa may then 
function as a coagulation enzyme causing thrombin forma- 
tion and eventual fibrin deposition (73), or as a regulator of 
endothelial cell function by inducing the elaboration of mito- 
gens. Thrombin results in the induction of more endothelial 
cell tissue factor, potentiating the activation of coagulation. 
This suggests a circle of interaction in which perturbation of 
endothelium leads to activation of coagulation, and products 
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Figure 6. Activation of Factor 
X on the endothelial cell sur- 
face  and  the  elaboration  of 
mitogenic activity. (A) Factor 
Xa  formation.  Endothelial 
cell  monolayers  were  incu- 
bated  with  Factor  VIII (1.5 
U/ml),  Factor  X  (300  nM), 
Factor IXa (0.2 nM), or active 
site-blocked  Factor  IXa (0.2 
nM). Aliquots of reaction mix- 
ture  supernatant  were  with- 
drawn  at the  indicated times 
and  assayed  for  Factor  Xa 
amidolytic  activity  as  de- 
scribed  in  Materials  and 
Methods. The mean of dupli- 
cates  is  shown. Where  indi- 
cated Factor IXa (e) was re- 
placed by active site-blocked 
Factor IXa (o) in the reaction 
mixture.  (B)  Elaboration  of 
mitogenic  activity.  Endothe- 
lial  cell  monolayers  were 
incubated for 3 h without co- 
agulation factors or with coagulation factors as described in A. Samples were assayed in the [3H]thymidine incorporation assay using 3T3 
cells. The mean of triplicates is shown. Standard deviations were <10%. I, no coagulation factors present;  II, Factors IXa, VIII, and X 
present;  HI, active site-blocked Factors IXa, VIII, and X present. 
of the activated coagulation system, Factor Xa and thrombin, 
perpetuate endothelial dysfunction. If this were true, then a 
nidus of perturbed endothelium promoting localized coagu- 
lation would also be a focus of mitogen release functioning 
before the  development of more advanced atherosclerotic 
lesions  characterized  by  endothelial  cell  denudation  and 
platelet deposition.  The role of endothelial  cell mitogens, 
however,  remains speculative and their ability to transmit 
proliferative signals within the vessel wall is unclear. 
The induction  of enhanced  endothelial  cell mitogen re- 
lease by Factor Xa was specific for the enzyme. Blockade of 
the active site by the physiologic inhibitor antithrombin HI 
or the low molecular agents diisopropylfluorophosphate or 
(p-amidinophenyl)methanesulfonyl fluoride  rendered  Fac- 
tor Xa ineffective in promoting mitogen release. Although 
initially this suggested the possibility of a mechanism involv- 
ing protease nexin, this inhibitor reacts with Factor Xa quite 
slowly (66). Furthermore, no higher molecular weight com- 
plexes were observed on SDS  PAGE when  L~SI-Factor Xa 
replaced Factor Xa in the incubation mixture. This is consis- 
tent with the results of two previous studies employing t25I- 
Factor Xa and cultured bovine endothelial cells (50, 59). The 
role of the enzyme's active site is unclear in mitogen release, 
but may involve proteolysis of a cell surface protein or per- 
haps even modification of a mitogen precursor promoting its 
release. The lack of a requirement for de novo transcription 
or translation for enhanced mitogen release induced by Fac- 
tor Xa is consistent with the notion that this enzyme may trig- 
ger posttranslational events leading to elaboration of growth 
factor activity. In this context, a  recent paper has demon- 
strated that a portion of the v-sis gene product is localized 
to  the  plasma membrane of simian  sarcoma virus  trans- 
formed cells (58). 
The lack of effective induction  of enhanced mitogen re- 
lease by Factor Xa modified by removal of the ~/-carboxyglu- 
tamic acid residues, which play a role in membrane interac- 
tions (52), suggested that cell surface binding of the enzyme 
might  be  involved.  In  this  context,  radioligand  studies 
identified a class of endothelial cell sites for Factor Xa whose 
binding parameters were similar to the lower range of Factor 
Xa concentrations  causing  mitogen release  (half-maximal 
binding and enhancement of mitogen release at Factor Xa 
concentrations of 0.8  and 0.5  nM,  respectively). Although 
this correlation may be fortuitous, it suggests that these sites 
may be related.  Growth factor release at higher concentra- 
tions of Factor Xa, however, did not correspond to an iden- 
tifiable class of binding sites and may represent a nonspecific 
protease effect rather than a specific Factor Xa-binding site 
interaction. Mitogen release in response to these higher con- 
centrations of Factor Xa did not saturate and thus appears to 
be similar to release of PDGFc in response to thrombin over 
the concentration range of 10-100  nM (32). 
These  data  reflect  the  close  relationship  between  the 
coagulation system and endothelium.  Factor Xa, a product 
of the activated coagulation mechanism, not only functions 
as a procoagulant, promoting thrombin formation on the cell 
surface, but can modulate endothelial cell physiology. Factor 
Xa can promote the release of mitogens,  elevate cytosolic 
calcium (71),  and finally be removed from the cell surface 
by receptor-mediated endocytosis (50).  Thrombin releases 
PDGFc directly  from the endothelium,  activates platelets, 
recruiting  them  to  augment  the  coagulant  response  and 
growth factor release, and induces endothelial cell procoagu- 
lant activity. This suggests a series of interactions in which 
perturbation of endothelium initiates procoagulant reactions 
on the vessel surface leading to Factor Xa and thrombin for- 
The Journal of Cell Biology, Volume  103, 1986  426 mation.  These coagulation  enzymes could then potentiate 
the perturbed state by enhancing localized mitogen release 
and close the circle of interaction by further promoting the 
generation of procoagulants. 
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